LH
FY2026 Q1 · Calendar Q2 2026
Labcorp Holdings Inc.
Labcorp's Q1 FY2026 reinforced the growth narrative from its full-year 2025 report. Both Diagnostics and Biopharma Laboratory Services contributed to solid enterprise revenue growth, driven by specialty and esoteric testing demand. Management raised the midpoint of full-year revenue and EPS guidance, signaling confidence that acquisitions, AI-driven efficiency gains, and specialty test expansion will offset weather-related softness and regulatory uncertainty. The company's broad partnership ecosystem and consumer health platform additions provide additional growth vectors. Policy risks around PAMA, CMS CRUSH, and ACA exchange enrollment warrant close monitoring but did not materially impair the quarter.
EPS surprise+3.4%
Market move-0.1%
